US7618567B2 - Absorbable sponge with contrasting agent - Google Patents

Absorbable sponge with contrasting agent Download PDF

Info

Publication number
US7618567B2
US7618567B2 US10/978,321 US97832104A US7618567B2 US 7618567 B2 US7618567 B2 US 7618567B2 US 97832104 A US97832104 A US 97832104A US 7618567 B2 US7618567 B2 US 7618567B2
Authority
US
United States
Prior art keywords
solution
pledget
gelatin
biopsy
foam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/978,321
Other versions
US20050059080A1 (en
Inventor
Eduardo Chi Sing
Mark Ashby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sub Q Inc
Boston Scientific Scimed Inc
Original Assignee
Boston Scientific Scimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/071,284 external-priority patent/US6162192A/en
Priority claimed from US09/071,670 external-priority patent/US6071301A/en
Application filed by Boston Scientific Scimed Inc filed Critical Boston Scientific Scimed Inc
Assigned to SUB-Q, INC. reassignment SUB-Q, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASHBY, MARK, SING, EDUARDO CHI
Priority to US10/978,321 priority Critical patent/US7618567B2/en
Publication of US20050059080A1 publication Critical patent/US20050059080A1/en
Priority to US12/578,088 priority patent/US20100029908A1/en
Publication of US7618567B2 publication Critical patent/US7618567B2/en
Application granted granted Critical
Priority to US12/887,945 priority patent/US20110014290A1/en
Priority to US13/776,952 priority patent/US20130172737A1/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/005Devices for introducing or retaining media, e.g. remedies, in cavities of the body for contrast media
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/02Instruments for taking cell samples or for biopsy
    • A61B10/0233Pointed or sharp biopsy instruments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/0057Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/02Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03Computerised tomographs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/48Diagnostic techniques
    • A61B6/481Diagnostic techniques involving the use of contrast agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/48Diagnostic techniques
    • A61B6/485Diagnostic techniques involving fluorescence X-ray imaging
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48Diagnostic techniques
    • A61B8/481Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00004(bio)absorbable, (bio)resorbable, resorptive
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/0057Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • A61B2017/00637Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for sealing trocar wounds through abdominal wall
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/0057Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • A61B2017/00646Type of implements
    • A61B2017/00654Type of implements entirely comprised between the two sides of the opening
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3933Liquid markers

Definitions

  • the invention relates to an absorbable sponge, and more particularly, the invention relates to the delivery of a contrasting agent to a specific area or site in a mammal after a surgical or interventional procedure.
  • the contrasting agent facilitates the location of the area or site even weeks or months after the initial procedure.
  • Percutaneous needle biopsy of solid organs is one of the most common interventional medical procedures. Millions of percutaneous needle biopsies are performed annually in the United States and throughout the world. Percutaneous biopsy is a safe procedure which has supplanted surgical biopsy for many indications, such as biopsy and liver biopsy.
  • Possible complications of needle biopsy include bleeding at the biopsy site.
  • the amount of bleeding is related to a number of factors including needle size, tissue sample size, patient's coagulation status, and the location of the biopsy site.
  • vascular organs such as the liver, a common biopsy target, may bleed significantly after needle biopsy.
  • Sterile sponges such as GELFOAM
  • GELFOAM Sterile sponges
  • the sponge sheets are left in the surgical site after surgery to stop bleeding and are absorbed by the body.
  • a number of techniques have used these absorbable sterile sponge materials to plug a biopsy tract to minimize or prevent bleeding.
  • the absorbable sponge provides a mechanical blockage of the tract, encourages clotting, and minimizes bleeding though the biopsy tract.
  • a mechanic clip device is often attached to the site where tissue is removed, so that if further treatment is later required the location of the site can be identified.
  • the time period between the biopsy and treatment may be weeks during which time the clip may become dislodged thereby making it difficult to relocate the site.
  • the present invention is based in part on the discovery that adding a contrasting agent (e.g, radiopaque agent) to an absorbable sponge provides for a material that not only facilitates hemostasis of a biopsy tract or other puncture wound but also permits precise identification of the site's location.
  • a contrasting agent e.g, radiopaque agent
  • the invention is directed to a method for marking a bodily site in a patient that includes the steps of:
  • the exact location of the bodily site can be located many weeks or longer following positioning of the absorbable sponge material.
  • the invention is directed to a method for performing a biopsy that included the steps of:
  • the invention is directed to a liquid permeable, absorbable, gelatin sponge that is prepared by a process that includes the steps of:
  • FIG. 1 is a side cross sectional view of an adaptor for delivery of a pledget to a needle
  • FIG. 2 is a side cross sectional view of a syringe for connection to the adaptor
  • FIG. 3 is a side cross sectional view of an adaptor and syringe combination with a pledget positioned within the adaptor;
  • FIG. 4 is a side cross sectional view of the loaded adaptor and syringe combination in preparation for connection to a biopsy needle;
  • FIG. 5 is a side cross sectional view of an alternative embodiment of an adaptor for delivery of a pledget including a template attached to the adaptor;
  • FIG. 6 is a top view of the template as it is used for cutting a pledget from an absorbable sponge sheet
  • FIG. 7 is a side cross sectional view of a portion of an organ and a system for delivering a pledget into a biopsy tract in the organ.
  • the present invention is directed to an absorbable sponge material containing a contrasting agent.
  • the absorbable sponge material is delivered to a specific area or site in a patient (i.e., mammal) after a surgical or interventional procedure.
  • the sponge material can be placed in the biopsy tract or other puncture wound and the contrasting agent enables marking or identification of the area or site.
  • the absorbable sponge will be described in connection with treatment of a biopsy tract after a percutaneous needle biopsy.
  • the absorbable sponge material can also exhibit secondary benefits of, for example, facilitating hemostasis and delivering therapeutic agents.
  • “Pledget” means a piece of absorbable sponge containing a contrasting agent preferably of a generally elongated shape having a size which allows injection in a hydrated state through a biopsy needle or other cannula.
  • “Sponge” means a biocompatible material which is capable of being hydrated and is resiliently compressible in a hydrated state.
  • the sponge is non-immunogenic and is absorbable.
  • “Absorbable sponge” means a sponge which when implanted within a patient (i.e., human or other mammalian body) is absorbed by the body.
  • the absorbable sponge contains a contrasting agent which may or may not be absorbable. Besides the contrasting agent, the sponge can also be used to deliver a beneficial agent such as thrombin, radiation treatment or the like.
  • “Bodily site” means any tissue in a mammal where the absorbable sponge containing the contrasting agent can be introduced.
  • the invention is particularly suited for introducing the absorbable sponge into tissue sites where further treatment may be required, for example, as in the case following biopsy.
  • “Hydrate” means to partially or fully saturate with a fluid, such as, saline, water, or the like.
  • “Kneading” of the absorbable sponge material means both dry and wet manipulation of the sponge material which compresses, enlarges, or changes the shape of the sponge material causing the sponge material to have improved expansion response.
  • “Contrasting agent” means a biocompatible material that is capable of being detected or monitored by fluoroscopy, X-ray photography, CAT scan, ultrasound, or similar imaging techniques following placement into a mammalian subject.
  • Preferred contrasting agents are radiopaque materials.
  • the contrast agent can be either water soluble or water insoluble. Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine. Examples of water insoluble contrast agents include tantalum, tantalum oxide, and barium sulfate, each of which is commercially available. Other water insoluble contrast agents include gold, tungsten, and platinum powders. Some radiopaque contrasting agents are available in liquid form.
  • the contrast agent is water insoluble (i.e., has a water solubility of less than 0.01 mg/ml at 20° C.).
  • the absorbable sponge material of the present invention is preferably a liquid permeable, water insoluble gelatin based sponge that has contrasting agent incorporated in the matrix of the sponge.
  • incorporated is meant that the contrasting agent is substantially dispersed throughout the sponge so that the contrasting material is not simply found on the periphery of the sponge.
  • the sponge is made by mixing a suitable organic solvent (e.g., formaldehyde) with an aqueous solution of gelatin.
  • the organic solvent facilitates the cross linkage of gelatin polymers. It is expected that glutaraldehyde may also be suitable.
  • the resulting solution is then incubated typically at slightly above room temperature (30°-40° C.). Subsequently, a contrasting agent is added and the resulting mixture beaten to produce a firm foam. Thereafter, the foam is dried to produce the absorbable sponge material.
  • the aqueous gelatin solution containing 3-10% gelatin by weight is prepared as a warm solution (e.g., 80° C.) to help dissolve the gelatin.
  • the solution is then allowed to cool (e.g, 35°-40° C.) before the organic solvent is added.
  • a preferred organic solvent is formalin (an aqueous solution of formaldehyde).
  • formalin an aqueous solution of formaldehyde.
  • the amount of formalin used will control the hardness of the sponge and its rate of absorption into the body. The more formalin used, the harder the sponge and the lower the absorption rate. Typically, the amount used is between 0.01 to 10% based on the gelatin solution.
  • the beating or whipping process takes about 5-15 or more minutes to produce a firm foam of about 4 to 8 times the volume of the original solution.
  • the drying process initially begins with oven drying in the presence of circulating air at about 30° to 33° C. or higher and 10% humidity. After the foam is thoroughly dried, the foam can be heated to an elevated temperature of about 140° C. for a sufficient length of time (e.g., 3 hrs) until the sponge is firm. Suitable absorbable sponge materials are further described in U.S. Pat. No. 2,465,357 which is incorporated herein by reference.
  • the contrasting agent must be added prior to beating the gelatin/formalin solution. The reason is that once the foam material is produced, the contrasting agent cannot be incorporated into the matrix of the sponge.
  • contrasting agents that are liquids it is preferred that they be added to the gelatin/formalin solution prior to being beaten to form the foam product. This will insure that the contrasting agent is dispersed throughout the sponge.
  • absorbable sponge materials containing different amounts of contrasting agent were prepared and tested. Specifically, 5 grams of pork gelatin (Bloom value 275) were mixed in 100 grams of water at 80° C. and the solution was allowed to cool to 35° C. before 0.03 cc of 40% formalin was added. The resulting solution was incubated at 35° C. for 2 hours before tantalum powder (50 to 150 grams) was added. The liquid was then vigorously mixed in a malt mixer to produce a foam. The foam was then oven dried at 35° C. for 12 hours.
  • the absorbable sponge material was examined with a fluoroscope and found to be extremely visible. Moreover, placement of the sponge material with contrasting agent in puncture sites of a swine model demonstrated that the absorbable sponge exhibited good hemostatic properties as well.
  • the sponge material with contrasting agent of the present invention is particularly suited for biopsies and other percutaneous procedures where knowledge of the site of initial treatment, e.g., tissue removal, is important.
  • the absorbable sponge material can be employed with any suitable medical instrument, a preferred device and method for facilitating hemostasis of a biopsy tract is described herein to illustrate use of the absorbable sponge material. This technique is further described in U.S. patent application Ser. No. 09/247,880, filed on Feb. 10, 1999, and entitled “Device and Method for Facilitating Hemostasis of a Biopsy Tract,” now U.S. Pat. No. 6,086,607, is incorporated herein by reference.
  • FIG. 1 shows the adaptor 12 in which the pledget 18 is placed for hydration and for delivery through the biopsy needle 16 .
  • the adaptor 12 allows pieces of absorbable sponge material with relatively large cross sections to be easily delivered through a biopsy needle 16 with a much smaller cross section.
  • the adaptor 12 also functions to remove air from the pledget 18 .
  • the adaptor 12 which delivers the hydrated pledget 18 to the needle 16 includes a first end 30 having an annular lip 32 or female luer fitting for connection to the syringe 14 .
  • a second end 34 of the adaptor 12 has a male luer fitting 36 for connection to a biopsy needle 16 or other cannula.
  • the luer fitting 36 includes a tapered external surface 38 and a retaining ring 40 with internal threads for receiving an annular lip of the biopsy needle.
  • the adaptor 12 has an internal lumen with a first diameter D 1 at the first end 30 and a second diameter D 2 at the second end 34 . Between the first and second ends of the adaptor 12 a tapered section 42 of the adaptor provides a funnel for compressing the hydrated pledget 18 prior to injection through the biopsy needle 16 and needle hub 28 .
  • the adaptor 12 may be formed in any known manner such as by molding from a plastic material.
  • the adaptor 12 is transparent so that the pledget 18 can be viewed through the adaptor and the user can visually monitor when the pledget is loaded within the adaptor and when the pledget has been delivered into the needle.
  • the adaptor lumen may be provided with a friction reducing coating for improved delivery. The delivery fluid also reduces friction for improved delivery by wetting the exterior surface of the pledget 18 .
  • the syringe 14 includes a male luer fitting 46 , a fluid chamber 48 , and a plunger 50 .
  • the first end 30 of the adaptor 12 is connectable to the luer fitting 46 of the conventional syringe 14 .
  • the syringe 14 may be provided with a spring 52 for automatic filling of the syringe 14 with a predetermined volume of fluid.
  • the biopsy needle 16 used with the present invention is preferably a co-axial biopsy needle, such as a bi-axial or a tri-axial biopsy needle.
  • a co-axial biopsy needle includes an outer needle or cannula through which a tissue sample is removed with a tissue scoop or other biopsy instrument. Once the tissue sample has been removed, the outer cannula remains in the patient as illustrated in FIG. 4 .
  • the cannula for delivery of the sponge pledget has been described as a biopsy needle, the cannula may be a catheter, sheath, or any other type of cannula.
  • FIG. 3 shows the loading and hydration of the pledget 18 within the adaptor 12 .
  • a pledget 18 is cut and placed within the adaptor 12 from the first end 30 of the adaptor.
  • the syringe 14 is filled with a predetermined amount of fluid, such as saline, and is connected to the first end 30 of the adaptor 12 by the luer fitting 46 .
  • the plunger 50 of the syringe 14 is then depressed slowly causing fluid to pass into the adaptor 12 , hydrating the pledget 18 , and filling the adaptor with a column of fluid.
  • the user waits a few seconds once the fluid is injected into the adaptor 12 until the pledget 18 is adequately hydrated creating a lubricous surface on the pledget.
  • the pledget 18 may expand within the adaptor to fill or nearly fill the lumen of the adaptor.
  • the adaptor 12 with the pledget 18 hydrated within the proximal end is ready to inject the pledget into a biopsy tract to facilitate hemostasis within the biopsy tract.
  • the adaptor 12 may be loaded prior to beginning the biopsy procedure.
  • the outer sheath of the biopsy needle 16 through which the biopsy has been taken is maintained in place within the biopsy tract, as shown in FIG. 4 .
  • the biopsy needle 16 provides pre-established targeting of the delivery site for delivery of the absorbable sponge pledget 18 and eliminates the uncertainty of re-access.
  • the luer fitting 36 of the adaptor 12 is connected to the biopsy needle hub 28 , as illustrated in FIG. 4 .
  • the biopsy needle 16 is withdrawn a short distance, such as about 1 to 20 mm, along the biopsy tract to provide space for the pledget 18 to be received in the biopsy tract. Additional fluid is then rapidly injected by the syringe to move the pledget 18 into the biopsy needle 16 .
  • the adaptor lumen When the adaptor lumen has been blocked by the hydrated pledget 18 which has swelled within the adaptor, injection of additional fluid will push the pledget through the tapered section 42 of the adaptor. If the adaptor lumen has not been entirely blocked by the pledget 18 , the venturi effect will help draw the pledget through the tapered section 42 of the adaptor.
  • the pledget 18 After the pledget 18 is moved to the biopsy needle 16 , the pledget 18 is then delivered from the needle 16 to the biopsy tract by rapid injection of additional fluid by the syringe 14 .
  • the hydrated pledget 18 quickly expands upon delivery to fill the available space in the biopsy tract to facilitate hemostasis and provide localized compression.
  • the absorbable sponge material of the present invention can be shaped into the required size by conventional means. Pledgets may be cut with a punch or a stencil or template and knife. Once hydrated, the pledget 18 can be easily compressed to fit into a lumen having a smaller cross sectional area than the original cross sectional area of the pledget. Additionally, the kneading of the hydrated pledget 18 during delivery encourages air trapped within the absorbable sponge to be expelled and replaced with fluid, allowing rapid expansion upon delivery.
  • Pledgets 118 with increased cross sectional area proximal ends may be prepared in a variety of manners.
  • the increased proximal mass can be achieved by cutting the pledget with an enlarged proximal end.
  • the pledget 118 may be formed by folding, rolling, compressing, or otherwise manipulating the sponge material to the desired shape.
  • the proximal pledget mass may also be increased by adding separate pieces of material to the proximal end of the pledget. This additional material may be layered, wrapped, coiled or attached to the pledget in any other manner.
  • the pledgets may also be formed by molding, bump extruding, dipping, or the like.
  • the larger cross sectional area proximal end is generally about 1.2 to 4 times the cross sectional area of the distal end.
  • the proximal end with the larger cross section area preferably extends along about 1 ⁇ 8 to 3 ⁇ 4 of the total pledget length.
  • the pledget 118 illustrated in FIG. 5 has been formed by cutting a strip of material from an absorbable sponge sheet 20 with the aid of the template 122 as illustrated in FIG. 6 . After the strip is cut, the proximal end of the strip is then folded back onto itself to form a pledget 118 with an increased cross sectional area and material mass at a proximal end.
  • a preferred embodiment of a pledget for delivery down a 20 gauge biopsy needle or cannula has a size of approximately 0.1 ⁇ 1.5 ⁇ 0.06 inches and is folded as illustrated in FIG. 5 to an overall length of about 0.9 inches. Placing this pledget 118 in an adaptor 112 having a largest internal diameter of 0.125 inches allows the pledget to be delivered to a 20 gauge or larger biopsy needle.
  • a pledget 118 maybe delivered through the cannula the biopsy site.
  • the pledget 118 for use in the system employing an 18 gauge or larger biopsy needle may be formed from a strip which is approximately 0.11-0.12 inches wide by about 3.125 inches long with a thickness of about 0.06 inches and folded to an overall length of about 2.2 inches. This pledget having a 28 which is attached to the distal end of the adaptor.
  • the pledget may be delivered to the biopsy tract by holding the biopsy needle or cannula 16 stationary and injecting the pledget through the biopsy needle. If additional pledgets are to be delivered, the biopsy needle 16 is withdrawn a distance sufficient to accommodate an additional pledget and the additional pledget is then injected.
  • An alternative method of delivering the pledget into the biopsy tract includes withdrawing the biopsy needle or cannula 16 during delivery of the pledget 18 to deliver the pledget in an elongated trail which follows the biopsy tract. Placing the absorbable sponge material in a trail which fills the entire biopsy tract provides the added benefit of providing hemostasis along the entire biopsy tract. This is particularly helpful for stopping the bleeding of biopsy tracts in organs which tend to have excessive bleeding such as the liver, kidney, spleen, and other vascular organs.
  • one method of the present invention involves the delivery of the pledget into the biopsy needle by a predetermined amount of fluid.
  • the biopsy needle is then withdrawn at a velocity V while the pledget material is ejected from the biopsy needle at a velocity E with respect to the biopsy needle.
  • the velocity V at which the biopsy needle is withdrawn is equal to or less than the velocity E at which the absorbable sponge material is delivered.
  • the control of injection of fluid and withdrawal of the needle to achieve the desired trail of absorbable sponge material in the biopsy tract maybe controlled with an injection controlling device.
  • the adaptor may be used to deliver the pledget into the biopsy needle 16 and then the adaptor is removed from the biopsy needle.
  • a plunger or stylet 80 which is generally provided with the biopsy needle 16 for inserting the biopsy needle is then used to deliver the pledget from the biopsy needle.
  • the biopsy needle extends through the tissue 84 and into the organ 86 for removal of a core of tissue.
  • the pledget is injected into the needle 16 and the plunger 80 is placed within the biopsy needle so that a distal end of the plunger abuts the proximal end of the pledget 118 .
  • the plunger 80 is then held stationary while the biopsy needle 16 is withdrawn from the biopsy site.
  • the plunger 80 causes the pledget 118 to be delivered in a trail 88 which fills the biopsy tract.
  • the trail 88 preferably extends along the entire biopsy tract to or past a surface of the organ 86 .
  • the delivery of the trail 88 of absorbable sponge material provides an advantage over the delivery of discrete blobs of material because the trail is able to provide hemostasis along the entire tract.
  • a blob of absorbable sponge material is delivered within the tract at a depth of 1-2 cm from the surface of the organs, this 1-2 cm of biopsy tract may continue to bleed significantly.
  • the pledget may be delivered as a plug.
  • the plunger 80 is advanced into the needle 16 pushing the pledget out of the distal end of the needle while the needle is held stationary.
  • a combination of delivery of plugs and trails may also be used.
  • the pledget material may be delivered entirely within a single anatomical structure or may cross two or more anatomical structures such as an organ, surrounding tissue and facial layer.
  • the biopsy needle 16 is retracted a distance sufficient to provide a space to accommodate an additional pledget 18 and the injection procedure described above is repeated for the additional pledget(s).
  • additional pledgets 18 may be injected beside an initially injected pledget until the cavity is filled.
  • biopsy is most commonly performed by biopsy needle, biopsy may also be performed through other cannulas, such as catheters, long needles, endoscopes, or the like.
  • the treatment procedure according to the present invention can be used for facilitating hemostasis of puncture wounds through different types of cannulas including needles, catheters, endoscopes, and the like.
  • the treatment procedure and systems according to the present invention may be used to deliver absorbable or non-absorbable sponge for other therapys.
  • sponge may be delivered for cosmetic or reconstructive bulking or for temporary or permanent intravascular embolization.
  • the absorbable sponge pledget 18 may be used to deliver a beneficial agent, such as, thrombin, radiation treatment, or the like.
  • the pledget can also be used to deliver therapeutic agents, such as radioactive isotopes for localized treatment of tumors, anti-cancer agents, anti-metastatic agents, and the like.
  • therapeutic agents such as radioactive isotopes for localized treatment of tumors, anti-cancer agents, anti-metastatic agents, and the like.
  • anti-cancer agents include 5-fluorouracil, cisplatin, prednisone, and others described in U.S. Pat. No. 4,619,913 which is incorporated herein by reference.
  • the absorbable sponge pledget 18 may be presoaked with the beneficial agent for delivery to the biopsy tract.
  • the pledget 18 may be hydrated with the beneficial liquid agent or the agent may be delivered to the pledget after the pledget is placed within the biopsy tract.
  • a pledget formed of inventive absorbable sponge material preferably will be absorbed by the body within 1 to 6 weeks. However, the pledget material may be designed to provide different rates of absorption. If the contrasting agent employed is also absorbable, the contrasting agent should be absorbed at approximately the same rate as the sponge material. Where the contrasting agent is non-absorbable, it will remain at the site.

Abstract

An absorbable sponge containing a contrasting agent (e.g, radiopaque agent) that can be introduced to a biopsy tract or other puncture wound site is provided. The contrasting agent permits identification of the site by fluoroscopy or other imaging techniques.

Description

This application is a divisional of U.S. application Ser. No. 09/966,611 filed Sep. 27, 2001, now abandoned, which is a continuation of U.S. application Ser. No. 09/630,814, filed Aug. 2, 2000, now abandoned, which is a divisional of U.S. application Ser. No. 09/335,452, filed Jun. 17, 1999, now U.S. Pat. No. 6,183,497, which is a continuation in part of U.S. application Ser. No. 09/071,670, filed May 1, 1998, now U.S. Pat. No. 6,071,301 and U.S. application Ser. No. 09/071,284, filed May 1, 1998, now U.S. Pat. No. 6,162,192.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to an absorbable sponge, and more particularly, the invention relates to the delivery of a contrasting agent to a specific area or site in a mammal after a surgical or interventional procedure. The contrasting agent facilitates the location of the area or site even weeks or months after the initial procedure.
2. Brief Description of the Related Art
Percutaneous needle biopsy of solid organs is one of the most common interventional medical procedures. Millions of percutaneous needle biopsies are performed annually in the United States and throughout the world. Percutaneous biopsy is a safe procedure which has supplanted surgical biopsy for many indications, such as biopsy and liver biopsy.
Possible complications of needle biopsy include bleeding at the biopsy site. The amount of bleeding is related to a number of factors including needle size, tissue sample size, patient's coagulation status, and the location of the biopsy site. Vascular organs such as the liver, a common biopsy target, may bleed significantly after needle biopsy.
Sterile sponges, such as GELFOAM, are prepared in dry sterile sheets which are used as packing material during surgery for control of bleeding. The sponge sheets are left in the surgical site after surgery to stop bleeding and are absorbed by the body. A number of techniques have used these absorbable sterile sponge materials to plug a biopsy tract to minimize or prevent bleeding. The absorbable sponge provides a mechanical blockage of the tract, encourages clotting, and minimizes bleeding though the biopsy tract.
During the biopsy, a mechanic clip device is often attached to the site where tissue is removed, so that if further treatment is later required the location of the site can be identified. Unfortunately, the time period between the biopsy and treatment may be weeks during which time the clip may become dislodged thereby making it difficult to relocate the site.
Accordingly, it would be desirable to provide a reliable technique for identifying biopsy sites or puncture wound sites.
SUMMARY OF THE INVENTION
The present invention is based in part on the discovery that adding a contrasting agent (e.g, radiopaque agent) to an absorbable sponge provides for a material that not only facilitates hemostasis of a biopsy tract or other puncture wound but also permits precise identification of the site's location.
Accordingly, in one aspect, the invention is directed to a method for marking a bodily site in a patient that includes the steps of:
identifying the bodily site; and
positioning a pledget of absorbable sponge material adjacent the bodily site wherein the absorbable sponge material includes a contrasting agent.
With the present invention, the exact location of the bodily site can be located many weeks or longer following positioning of the absorbable sponge material.
In another aspect, the invention is directed to a method for performing a biopsy that included the steps of:
removing tissue from a vascular tissue site; and
positioning a pledget of absorbable sponge material adjacent the vascular tissue site wherein the absorbable sponge material includes a contrasting agent.
In another aspect, the invention is directed to a liquid permeable, absorbable, gelatin sponge that is prepared by a process that includes the steps of:
(a) preparing an aqueous gelatin solution;
(b) adding an organic solvent in the aqueous gelatin solution to form a second solution;
(c) incubating the second solution;
(d) forming a foam from the second solution wherein a contrasting agent is added to the second solution at any step prior to forming the foam; and
(e) drying the foam.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
FIG. 1 is a side cross sectional view of an adaptor for delivery of a pledget to a needle;
FIG. 2 is a side cross sectional view of a syringe for connection to the adaptor;
FIG. 3 is a side cross sectional view of an adaptor and syringe combination with a pledget positioned within the adaptor;
FIG. 4 is a side cross sectional view of the loaded adaptor and syringe combination in preparation for connection to a biopsy needle;
FIG. 5 is a side cross sectional view of an alternative embodiment of an adaptor for delivery of a pledget including a template attached to the adaptor;
FIG. 6 is a top view of the template as it is used for cutting a pledget from an absorbable sponge sheet; and
FIG. 7 is a side cross sectional view of a portion of an organ and a system for delivering a pledget into a biopsy tract in the organ.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is directed to an absorbable sponge material containing a contrasting agent. The absorbable sponge material is delivered to a specific area or site in a patient (i.e., mammal) after a surgical or interventional procedure. For example, the sponge material can be placed in the biopsy tract or other puncture wound and the contrasting agent enables marking or identification of the area or site. The absorbable sponge will be described in connection with treatment of a biopsy tract after a percutaneous needle biopsy. The absorbable sponge material can also exhibit secondary benefits of, for example, facilitating hemostasis and delivering therapeutic agents.
Prior to discussing the present invention in further detail, the following terms are defined:
“Pledget” means a piece of absorbable sponge containing a contrasting agent preferably of a generally elongated shape having a size which allows injection in a hydrated state through a biopsy needle or other cannula.
“Sponge” means a biocompatible material which is capable of being hydrated and is resiliently compressible in a hydrated state. Preferably, the sponge is non-immunogenic and is absorbable.
“Absorbable sponge” means a sponge which when implanted within a patient (i.e., human or other mammalian body) is absorbed by the body. The absorbable sponge contains a contrasting agent which may or may not be absorbable. Besides the contrasting agent, the sponge can also be used to deliver a beneficial agent such as thrombin, radiation treatment or the like.
“Bodily site” means any tissue in a mammal where the absorbable sponge containing the contrasting agent can be introduced. The invention is particularly suited for introducing the absorbable sponge into tissue sites where further treatment may be required, for example, as in the case following biopsy.
“Hydrate” means to partially or fully saturate with a fluid, such as, saline, water, or the like.
“Kneading” of the absorbable sponge material means both dry and wet manipulation of the sponge material which compresses, enlarges, or changes the shape of the sponge material causing the sponge material to have improved expansion response.
“Contrasting agent” means a biocompatible material that is capable of being detected or monitored by fluoroscopy, X-ray photography, CAT scan, ultrasound, or similar imaging techniques following placement into a mammalian subject. Preferred contrasting agents are radiopaque materials. The contrast agent can be either water soluble or water insoluble. Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine. Examples of water insoluble contrast agents include tantalum, tantalum oxide, and barium sulfate, each of which is commercially available. Other water insoluble contrast agents include gold, tungsten, and platinum powders. Some radiopaque contrasting agents are available in liquid form. These include, for example, OMNIPAQUE from Nycomed, Inc., Princeton, N.J. Preferably, the contrast agent is water insoluble (i.e., has a water solubility of less than 0.01 mg/ml at 20° C.).
The absorbable sponge material of the present invention is preferably a liquid permeable, water insoluble gelatin based sponge that has contrasting agent incorporated in the matrix of the sponge. By “incorporated” is meant that the contrasting agent is substantially dispersed throughout the sponge so that the contrasting material is not simply found on the periphery of the sponge. The sponge is made by mixing a suitable organic solvent (e.g., formaldehyde) with an aqueous solution of gelatin. The organic solvent facilitates the cross linkage of gelatin polymers. It is expected that glutaraldehyde may also be suitable. The resulting solution is then incubated typically at slightly above room temperature (30°-40° C.). Subsequently, a contrasting agent is added and the resulting mixture beaten to produce a firm foam. Thereafter, the foam is dried to produce the absorbable sponge material.
Typically, the aqueous gelatin solution containing 3-10% gelatin by weight is prepared as a warm solution (e.g., 80° C.) to help dissolve the gelatin. The solution is then allowed to cool (e.g, 35°-40° C.) before the organic solvent is added. A preferred organic solvent is formalin (an aqueous solution of formaldehyde). The amount of formalin used will control the hardness of the sponge and its rate of absorption into the body. The more formalin used, the harder the sponge and the lower the absorption rate. Typically, the amount used is between 0.01 to 10% based on the gelatin solution. The beating or whipping process takes about 5-15 or more minutes to produce a firm foam of about 4 to 8 times the volume of the original solution. The drying process initially begins with oven drying in the presence of circulating air at about 30° to 33° C. or higher and 10% humidity. After the foam is thoroughly dried, the foam can be heated to an elevated temperature of about 140° C. for a sufficient length of time (e.g., 3 hrs) until the sponge is firm. Suitable absorbable sponge materials are further described in U.S. Pat. No. 2,465,357 which is incorporated herein by reference.
It has been found that at least for contrasting agents that are not soluble in water, the contrasting agent must be added prior to beating the gelatin/formalin solution. The reason is that once the foam material is produced, the contrasting agent cannot be incorporated into the matrix of the sponge.
When employing contrasting agents that are liquids it is preferred that they be added to the gelatin/formalin solution prior to being beaten to form the foam product. This will insure that the contrasting agent is dispersed throughout the sponge.
Care should be taken when using insoluble contrasting agents not to overload the absorbable sponge material by using excessive amounts of contrasting agents. This will possibly result in sponges that have reduced cell structures, that is, the final volume will be significantly less than if no contrasting agent was used.
Following the above formulation, absorbable sponge materials containing different amounts of contrasting agent were prepared and tested. Specifically, 5 grams of pork gelatin (Bloom value 275) were mixed in 100 grams of water at 80° C. and the solution was allowed to cool to 35° C. before 0.03 cc of 40% formalin was added. The resulting solution was incubated at 35° C. for 2 hours before tantalum powder (50 to 150 grams) was added. The liquid was then vigorously mixed in a malt mixer to produce a foam. The foam was then oven dried at 35° C. for 12 hours.
The absorbable sponge material was examined with a fluoroscope and found to be extremely visible. Moreover, placement of the sponge material with contrasting agent in puncture sites of a swine model demonstrated that the absorbable sponge exhibited good hemostatic properties as well.
The sponge material with contrasting agent of the present invention is particularly suited for biopsies and other percutaneous procedures where knowledge of the site of initial treatment, e.g., tissue removal, is important.
While the absorbable sponge material can be employed with any suitable medical instrument, a preferred device and method for facilitating hemostasis of a biopsy tract is described herein to illustrate use of the absorbable sponge material. This technique is further described in U.S. patent application Ser. No. 09/247,880, filed on Feb. 10, 1999, and entitled “Device and Method for Facilitating Hemostasis of a Biopsy Tract,” now U.S. Pat. No. 6,086,607, is incorporated herein by reference.
FIG. 1 shows the adaptor 12 in which the pledget 18 is placed for hydration and for delivery through the biopsy needle 16. The adaptor 12 allows pieces of absorbable sponge material with relatively large cross sections to be easily delivered through a biopsy needle 16 with a much smaller cross section. The adaptor 12 also functions to remove air from the pledget 18.
The adaptor 12 which delivers the hydrated pledget 18 to the needle 16 includes a first end 30 having an annular lip 32 or female luer fitting for connection to the syringe 14. A second end 34 of the adaptor 12 has a male luer fitting 36 for connection to a biopsy needle 16 or other cannula. The luer fitting 36 includes a tapered external surface 38 and a retaining ring 40 with internal threads for receiving an annular lip of the biopsy needle. The adaptor 12 has an internal lumen with a first diameter D1 at the first end 30 and a second diameter D2 at the second end 34. Between the first and second ends of the adaptor 12 a tapered section 42 of the adaptor provides a funnel for compressing the hydrated pledget 18 prior to injection through the biopsy needle 16 and needle hub 28.
The adaptor 12 may be formed in any known manner such as by molding from a plastic material. Preferably, the adaptor 12 is transparent so that the pledget 18 can be viewed through the adaptor and the user can visually monitor when the pledget is loaded within the adaptor and when the pledget has been delivered into the needle. The adaptor lumen may be provided with a friction reducing coating for improved delivery. The delivery fluid also reduces friction for improved delivery by wetting the exterior surface of the pledget 18.
As shown in FIG. 2, the syringe 14 includes a male luer fitting 46, a fluid chamber 48, and a plunger 50. The first end 30 of the adaptor 12 is connectable to the luer fitting 46 of the conventional syringe 14. The syringe 14 may be provided with a spring 52 for automatic filling of the syringe 14 with a predetermined volume of fluid.
The biopsy needle 16 used with the present invention is preferably a co-axial biopsy needle, such as a bi-axial or a tri-axial biopsy needle. A co-axial biopsy needle includes an outer needle or cannula through which a tissue sample is removed with a tissue scoop or other biopsy instrument. Once the tissue sample has been removed, the outer cannula remains in the patient as illustrated in FIG. 4. Although the cannula for delivery of the sponge pledget has been described as a biopsy needle, the cannula may be a catheter, sheath, or any other type of cannula.
A preferred method of facilitating hemostasis of a biopsy tract will be described with reference to FIG. 3 which shows the loading and hydration of the pledget 18 within the adaptor 12. A pledget 18 is cut and placed within the adaptor 12 from the first end 30 of the adaptor. The syringe 14 is filled with a predetermined amount of fluid, such as saline, and is connected to the first end 30 of the adaptor 12 by the luer fitting 46. The plunger 50 of the syringe 14 is then depressed slowly causing fluid to pass into the adaptor 12, hydrating the pledget 18, and filling the adaptor with a column of fluid. Care should be taken to inject the fluid slowly to prevent the pledget from being ejected out of the second end 34 of the adaptor. Preferably, the user waits a few seconds once the fluid is injected into the adaptor 12 until the pledget 18 is adequately hydrated creating a lubricous surface on the pledget. The pledget 18 may expand within the adaptor to fill or nearly fill the lumen of the adaptor. The adaptor 12 with the pledget 18 hydrated within the proximal end is ready to inject the pledget into a biopsy tract to facilitate hemostasis within the biopsy tract. The adaptor 12 may be loaded prior to beginning the biopsy procedure.
After the biopsy procedure has been completed, the outer sheath of the biopsy needle 16 through which the biopsy has been taken is maintained in place within the biopsy tract, as shown in FIG. 4. The biopsy needle 16 provides pre-established targeting of the delivery site for delivery of the absorbable sponge pledget 18 and eliminates the uncertainty of re-access. The luer fitting 36 of the adaptor 12 is connected to the biopsy needle hub 28, as illustrated in FIG. 4. The biopsy needle 16 is withdrawn a short distance, such as about 1 to 20 mm, along the biopsy tract to provide space for the pledget 18 to be received in the biopsy tract. Additional fluid is then rapidly injected by the syringe to move the pledget 18 into the biopsy needle 16. When the adaptor lumen has been blocked by the hydrated pledget 18 which has swelled within the adaptor, injection of additional fluid will push the pledget through the tapered section 42 of the adaptor. If the adaptor lumen has not been entirely blocked by the pledget 18, the venturi effect will help draw the pledget through the tapered section 42 of the adaptor. After the pledget 18 is moved to the biopsy needle 16, the pledget 18 is then delivered from the needle 16 to the biopsy tract by rapid injection of additional fluid by the syringe 14. The hydrated pledget 18 quickly expands upon delivery to fill the available space in the biopsy tract to facilitate hemostasis and provide localized compression.
The absorbable sponge material of the present invention can be shaped into the required size by conventional means. Pledgets may be cut with a punch or a stencil or template and knife. Once hydrated, the pledget 18 can be easily compressed to fit into a lumen having a smaller cross sectional area than the original cross sectional area of the pledget. Additionally, the kneading of the hydrated pledget 18 during delivery encourages air trapped within the absorbable sponge to be expelled and replaced with fluid, allowing rapid expansion upon delivery.
When delivering a pledget 118 of absorbable sponge material, it is important to deliver a desired amount of the sponge material using a minimum amount of fluid.
Pledgets 118 with increased cross sectional area proximal ends may be prepared in a variety of manners. For example, if a pledget 118 is prepared from a sheet of sponge material, the increased proximal mass can be achieved by cutting the pledget with an enlarged proximal end. Alternatively, the pledget 118 may be formed by folding, rolling, compressing, or otherwise manipulating the sponge material to the desired shape. The proximal pledget mass may also be increased by adding separate pieces of material to the proximal end of the pledget. This additional material may be layered, wrapped, coiled or attached to the pledget in any other manner. The pledgets may also be formed by molding, bump extruding, dipping, or the like. The larger cross sectional area proximal end is generally about 1.2 to 4 times the cross sectional area of the distal end. In addition, the proximal end with the larger cross section area preferably extends along about ⅛ to ¾ of the total pledget length.
The pledget 118 illustrated in FIG. 5 has been formed by cutting a strip of material from an absorbable sponge sheet 20 with the aid of the template 122 as illustrated in FIG. 6. After the strip is cut, the proximal end of the strip is then folded back onto itself to form a pledget 118 with an increased cross sectional area and material mass at a proximal end. One example of a preferred embodiment of a pledget for delivery down a 20 gauge biopsy needle or cannula has a size of approximately 0.1×1.5×0.06 inches and is folded as illustrated in FIG. 5 to an overall length of about 0.9 inches. Placing this pledget 118 in an adaptor 112 having a largest internal diameter of 0.125 inches allows the pledget to be delivered to a 20 gauge or larger biopsy needle. Other common biopsy procedures use an 18 gauge or larger biopsy needle through a slightly larger guide cannula and would receive a somewhat larger pledget. After taking a core sample and removing the biopsy needle from the cannula guide, a pledget 118 maybe delivered through the cannula the biopsy site. The pledget 118 for use in the system employing an 18 gauge or larger biopsy needle may be formed from a strip which is approximately 0.11-0.12 inches wide by about 3.125 inches long with a thickness of about 0.06 inches and folded to an overall length of about 2.2 inches. This pledget having a 28 which is attached to the distal end of the adaptor.
As described above, the pledget may be delivered to the biopsy tract by holding the biopsy needle or cannula 16 stationary and injecting the pledget through the biopsy needle. If additional pledgets are to be delivered, the biopsy needle 16 is withdrawn a distance sufficient to accommodate an additional pledget and the additional pledget is then injected.
An alternative method of delivering the pledget into the biopsy tract includes withdrawing the biopsy needle or cannula 16 during delivery of the pledget 18 to deliver the pledget in an elongated trail which follows the biopsy tract. Placing the absorbable sponge material in a trail which fills the entire biopsy tract provides the added benefit of providing hemostasis along the entire biopsy tract. This is particularly helpful for stopping the bleeding of biopsy tracts in organs which tend to have excessive bleeding such as the liver, kidney, spleen, and other vascular organs.
In order to achieve a trail of absorbable sponge material in the biopsy tract, one method of the present invention involves the delivery of the pledget into the biopsy needle by a predetermined amount of fluid. The biopsy needle is then withdrawn at a velocity V while the pledget material is ejected from the biopsy needle at a velocity E with respect to the biopsy needle. The velocity V at which the biopsy needle is withdrawn is equal to or less than the velocity E at which the absorbable sponge material is delivered. The control of injection of fluid and withdrawal of the needle to achieve the desired trail of absorbable sponge material in the biopsy tract maybe controlled with an injection controlling device.
According to an alternative embodiment as illustrated in FIG. 7, the adaptor may be used to deliver the pledget into the biopsy needle 16 and then the adaptor is removed from the biopsy needle. A plunger or stylet 80 which is generally provided with the biopsy needle 16 for inserting the biopsy needle is then used to deliver the pledget from the biopsy needle. As shown in FIG. 7, the biopsy needle extends through the tissue 84 and into the organ 86 for removal of a core of tissue. After biopsy, the pledget is injected into the needle 16 and the plunger 80 is placed within the biopsy needle so that a distal end of the plunger abuts the proximal end of the pledget 118. The plunger 80 is then held stationary while the biopsy needle 16 is withdrawn from the biopsy site. The plunger 80 causes the pledget 118 to be delivered in a trail 88 which fills the biopsy tract. The trail 88 preferably extends along the entire biopsy tract to or past a surface of the organ 86. The delivery of the trail 88 of absorbable sponge material provides an advantage over the delivery of discrete blobs of material because the trail is able to provide hemostasis along the entire tract. In contrast, if a blob of absorbable sponge material is delivered within the tract at a depth of 1-2 cm from the surface of the organs, this 1-2 cm of biopsy tract may continue to bleed significantly.
As an alternative to delivery of the pledget as a trail, the pledget may be delivered as a plug. To deliver a plug the plunger 80 is advanced into the needle 16 pushing the pledget out of the distal end of the needle while the needle is held stationary. A combination of delivery of plugs and trails may also be used. The pledget material may be delivered entirely within a single anatomical structure or may cross two or more anatomical structures such as an organ, surrounding tissue and facial layer.
In some instances it may be desirable to deliver multiple pledgets in spaced apart positions along the biopsy tract, particularly for a long biopsy tract. For delivery of additional pledgets, the biopsy needle 16 is retracted a distance sufficient to provide a space to accommodate an additional pledget 18 and the injection procedure described above is repeated for the additional pledget(s). For a particularly large biopsy site or cavity, additional pledgets 18 may be injected beside an initially injected pledget until the cavity is filled.
Although biopsy is most commonly performed by biopsy needle, biopsy may also be performed through other cannulas, such as catheters, long needles, endoscopes, or the like. The treatment procedure according to the present invention can be used for facilitating hemostasis of puncture wounds through different types of cannulas including needles, catheters, endoscopes, and the like. In addition, the treatment procedure and systems according to the present invention may be used to deliver absorbable or non-absorbable sponge for other therapys. For example, sponge may be delivered for cosmetic or reconstructive bulking or for temporary or permanent intravascular embolization.
In addition to the contrasting agent, the absorbable sponge pledget 18 may be used to deliver a beneficial agent, such as, thrombin, radiation treatment, or the like. The pledget can also be used to deliver therapeutic agents, such as radioactive isotopes for localized treatment of tumors, anti-cancer agents, anti-metastatic agents, and the like. Examples of anti-cancer agents include 5-fluorouracil, cisplatin, prednisone, and others described in U.S. Pat. No. 4,619,913 which is incorporated herein by reference. The absorbable sponge pledget 18 may be presoaked with the beneficial agent for delivery to the biopsy tract. Alternatively, the pledget 18 may be hydrated with the beneficial liquid agent or the agent may be delivered to the pledget after the pledget is placed within the biopsy tract.
A pledget formed of inventive absorbable sponge material preferably will be absorbed by the body within 1 to 6 weeks. However, the pledget material may be designed to provide different rates of absorption. If the contrasting agent employed is also absorbable, the contrasting agent should be absorbed at approximately the same rate as the sponge material. Where the contrasting agent is non-absorbable, it will remain at the site.
While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.

Claims (16)

1. A liquid permeable, absorbable gelatin sponge that is prepared by a process that comprises:
(a) preparing an aqueous gelatin solution;
(b) adding an organic solvent in the aqueous gelatin solution to form a second solution;
(c) incubating the second solution;
(d) forming a foam from the second solution wherein a contrasting agent is added to the second solution at any step prior to forming the foam; and
(e) drying the foam.
2. The gelatin sponge of claim 1 wherein said forming comprises whipping the second solution until a foam is produced.
3. The gelatin sponge of claim 1 wherein said organic solvent is a formaldehyde solution.
4. The gelatin sponge of claim 1 wherein said preparing further comprises warming the aqueous gelatin solution.
5. The gelatin sponge of claim 4 wherein said warming further comprises cooling the aqueous gelatin solution before adding the organic solvent.
6. The gelatin sponge of claim 1 wherein said process further comprises heating the foam.
7. The gelatin sponge of claim 1 wherein said process further comprises soaking the foam with a beneficial agent.
8. The gelatin sponge of claim 1 wherein said process further comprises hydrating the foam with a beneficial agent.
9. A process to prepare a liquid permeable, absorbable gelatin sponge, comprising:
preparing an aqueous gelatin solution;
adding a formalin solution to the gelatin solution thereby forming a second solution;
incubating the second solution; mixing the second solution thereby forming a foam;
incorporating a contrasting agent to the second solution as the foam is formed;
drying the foam.
10. The process of claim 9 wherein said preparing further comprises mixing a gelatin with a warm aqueous solution.
11. The process of claim 10 wherein said gelatin is a pork gelatin.
12. The process of claim 10 further comprising cooling the gelatin solution.
13. The process of claim 10 wherein the aqueous solution is water.
14. The process of claim 9 wherein said contrasting agent is a tantalum powder.
15. The process of claim 9 further comprising soaking the foam with a beneficial agent.
16. The process of claim 9 further comprising hydrating the foam with a beneficial agent.
US10/978,321 1995-09-15 2004-10-29 Absorbable sponge with contrasting agent Expired - Fee Related US7618567B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/978,321 US7618567B2 (en) 1998-05-01 2004-10-29 Absorbable sponge with contrasting agent
US12/578,088 US20100029908A1 (en) 1998-05-01 2009-10-13 Absorbable sponge with contrasting agent
US12/887,945 US20110014290A1 (en) 1995-09-15 2010-09-22 System and method for facilitating hemostasis with an absorbable sponge
US13/776,952 US20130172737A1 (en) 1998-05-01 2013-02-26 Absorbable sponge with contrasting agent

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/071,670 US6071301A (en) 1998-05-01 1998-05-01 Device and method for facilitating hemostasis of a biopsy tract
US09/071,284 US6162192A (en) 1998-05-01 1998-05-01 System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US09/335,452 US6183497B1 (en) 1998-05-01 1999-06-17 Absorbable sponge with contrasting agent
US63081400A 2000-08-02 2000-08-02
US09/966,611 US20020038133A1 (en) 1998-05-01 2001-09-27 Absorbable sponge with contrasting agent
US10/978,321 US7618567B2 (en) 1998-05-01 2004-10-29 Absorbable sponge with contrasting agent

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/966,611 Division US20020038133A1 (en) 1995-09-15 2001-09-27 Absorbable sponge with contrasting agent
US09/996,611 Division US6903200B1 (en) 2000-12-27 2001-11-30 Human α1 chain collagen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/578,088 Continuation US20100029908A1 (en) 1995-09-15 2009-10-13 Absorbable sponge with contrasting agent

Publications (2)

Publication Number Publication Date
US20050059080A1 US20050059080A1 (en) 2005-03-17
US7618567B2 true US7618567B2 (en) 2009-11-17

Family

ID=23311845

Family Applications (5)

Application Number Title Priority Date Filing Date
US09/335,452 Expired - Lifetime US6183497B1 (en) 1995-09-15 1999-06-17 Absorbable sponge with contrasting agent
US09/966,611 Abandoned US20020038133A1 (en) 1995-09-15 2001-09-27 Absorbable sponge with contrasting agent
US10/978,321 Expired - Fee Related US7618567B2 (en) 1995-09-15 2004-10-29 Absorbable sponge with contrasting agent
US12/578,088 Abandoned US20100029908A1 (en) 1995-09-15 2009-10-13 Absorbable sponge with contrasting agent
US13/776,952 Abandoned US20130172737A1 (en) 1998-05-01 2013-02-26 Absorbable sponge with contrasting agent

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/335,452 Expired - Lifetime US6183497B1 (en) 1995-09-15 1999-06-17 Absorbable sponge with contrasting agent
US09/966,611 Abandoned US20020038133A1 (en) 1995-09-15 2001-09-27 Absorbable sponge with contrasting agent

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/578,088 Abandoned US20100029908A1 (en) 1995-09-15 2009-10-13 Absorbable sponge with contrasting agent
US13/776,952 Abandoned US20130172737A1 (en) 1998-05-01 2013-02-26 Absorbable sponge with contrasting agent

Country Status (6)

Country Link
US (5) US6183497B1 (en)
EP (1) EP1191884A1 (en)
JP (1) JP4460203B2 (en)
AU (1) AU5877200A (en)
CA (1) CA2371841A1 (en)
WO (1) WO2000078228A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642658B2 (en) 2008-10-15 2017-05-09 Orthoclip Llc Device and method for delivery of therapeutic agents via internal implants
US10643371B2 (en) 2014-08-11 2020-05-05 Covidien Lp Treatment procedure planning system and method

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508504A (en) * 1994-09-16 1998-08-25 バイオプシス メディカル インコーポレイテッド Method and apparatus for identifying and marking tissue
US6071301A (en) 1998-05-01 2000-06-06 Sub Q., Inc. Device and method for facilitating hemostasis of a biopsy tract
US6071300A (en) * 1995-09-15 2000-06-06 Sub-Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US6183497B1 (en) * 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US6270464B1 (en) * 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
US6161034A (en) * 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6347241B2 (en) 1999-02-02 2002-02-12 Senorx, Inc. Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it
US20010045575A1 (en) * 1998-05-01 2001-11-29 Mark Ashby Device and method for facilitating hemostasis of a biopsy tract
US6200328B1 (en) 1998-05-01 2001-03-13 Sub Q, Incorporated Device and method for facilitating hemostasis of a biopsy tract
US6610026B2 (en) 1998-05-01 2003-08-26 Sub-Q, Inc. Method of hydrating a sponge material for delivery to a body
US6315753B1 (en) * 1998-05-01 2001-11-13 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US20020058882A1 (en) * 1998-06-22 2002-05-16 Artemis Medical, Incorporated Biopsy localization method and device
US6356782B1 (en) 1998-12-24 2002-03-12 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US9669113B1 (en) 1998-12-24 2017-06-06 Devicor Medical Products, Inc. Device and method for safe location and marking of a biopsy cavity
US6371904B1 (en) * 1998-12-24 2002-04-16 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US20080039819A1 (en) * 2006-08-04 2008-02-14 Senorx, Inc. Marker formed of starch or other suitable polysaccharide
US20090030309A1 (en) * 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US6725083B1 (en) * 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US7651505B2 (en) * 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
JP4271375B2 (en) * 1999-02-10 2009-06-03 サブ−キュー・インコーポレーテッド Device and method for facilitating hemostasis in a biopsy duct
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
US7695492B1 (en) 1999-09-23 2010-04-13 Boston Scientific Scimed, Inc. Enhanced bleed back system
WO2002041786A2 (en) 2000-11-20 2002-05-30 Senorx, Inc. Tissue site markers for in vivo imaging
WO2002087636A1 (en) * 2001-03-12 2002-11-07 Sub-Q, Inc. Methods for sterilizing cross-linked gelatin compositions
US8187625B2 (en) 2001-03-12 2012-05-29 Boston Scientific Scimed, Inc. Cross-linked gelatin composition comprising a wetting agent
US6511457B2 (en) * 2001-05-04 2003-01-28 Garey Thompson Airless syringe
US7008440B2 (en) * 2001-11-08 2006-03-07 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US6863680B2 (en) * 2001-11-08 2005-03-08 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
CA2452040C (en) * 2001-06-29 2011-03-22 Cook Biotech Incorporated Porous sponge matrix medical devices and methods
US7037323B2 (en) * 2001-11-08 2006-05-02 Sub-Q, Inc. Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7192436B2 (en) * 2001-11-08 2007-03-20 Sub-Q, Inc. Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7025748B2 (en) * 2001-11-08 2006-04-11 Boston Scientific Scimed, Inc. Sheath based blood vessel puncture locator and depth indicator
AU2003231312B2 (en) * 2002-05-06 2008-10-23 Drexel University Tissue joining devices capable of delivery of bioactive agents and methods for use thereof
US20040102730A1 (en) * 2002-10-22 2004-05-27 Davis Thomas P. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
AU2003275607A1 (en) * 2002-10-24 2004-05-13 Terumo Kabushiki Kaisha Method of producing syringe, cap, and prefilled syringe
US7455680B1 (en) 2002-11-04 2008-11-25 Boston Scientific Scimed, Inc. Apparatus and method for inhibiting blood loss
US8317821B1 (en) 2002-11-04 2012-11-27 Boston Scientific Scimed, Inc. Release mechanism
US7955353B1 (en) 2002-11-04 2011-06-07 Sub-Q, Inc. Dissolvable closure device
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US8709038B2 (en) * 2002-12-20 2014-04-29 Boston Scientific Scimed, Inc. Puncture hole sealing device
US20040122349A1 (en) * 2002-12-20 2004-06-24 Lafontaine Daniel M. Closure device with textured surface
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US20050119562A1 (en) * 2003-05-23 2005-06-02 Senorx, Inc. Fibrous marker formed of synthetic polymer strands
US7942897B2 (en) * 2003-07-10 2011-05-17 Boston Scientific Scimed, Inc. System for closing an opening in a body cavity
US20050020899A1 (en) * 2003-07-25 2005-01-27 Rubicor Medical, Inc. Post-biopsy cavity treatmetn implants and methods
US7537788B2 (en) * 2003-07-25 2009-05-26 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US7744852B2 (en) 2003-07-25 2010-06-29 Rubicor Medical, Llc Methods and systems for marking post biopsy cavity sites
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US7875043B1 (en) 2003-12-09 2011-01-25 Sub-Q, Inc. Cinching loop
US20050234336A1 (en) * 2004-03-26 2005-10-20 Beckman Andrew T Apparatus and method for marking tissue
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
CA2562580C (en) 2005-10-07 2014-04-29 Inrad, Inc. Drug-eluting tissue marker
US20080234532A1 (en) * 2005-10-22 2008-09-25 Invibio Limited Fiducial marker
GB0521536D0 (en) * 2005-10-22 2005-11-30 Invibio Ltd Fiducial marker
US20070129630A1 (en) * 2005-12-07 2007-06-07 Shimko Daniel A Imaging method, device and system
US20070135706A1 (en) * 2005-12-13 2007-06-14 Shimko Daniel A Debridement method, device and kit
US8673398B2 (en) * 2006-02-23 2014-03-18 Meadwestvaco Corporation Method for treating a substrate
ES2443526T3 (en) 2006-10-23 2014-02-19 C.R. Bard, Inc. Breast marker
WO2008073965A2 (en) 2006-12-12 2008-06-19 C.R. Bard Inc. Multiple imaging mode tissue marker
WO2008076973A2 (en) 2006-12-18 2008-06-26 C.R.Bard Inc. Biopsy marker with in situ-generated imaging properties
WO2009099767A2 (en) 2008-01-31 2009-08-13 C.R. Bard, Inc. Biopsy tissue marker
JP2011518621A (en) * 2008-04-25 2011-06-30 ザイモジェネティクス, インコーポレイテッド Medical device for delivering fluid during surgery and method of use thereof
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
JP5453453B2 (en) 2008-12-30 2014-03-26 シー・アール・バード・インコーポレーテッド Marker transmission device for placement of tissue markers
US9198987B2 (en) 2010-06-25 2015-12-01 Kci Licensing, Inc. Systems and methods for imaging sinuses
EP2649192A4 (en) 2010-12-08 2014-05-14 Expression Pathology Inc Truncated her2 srm/mrm assay
WO2014081940A1 (en) * 2012-11-21 2014-05-30 Trustees Of Boston University Tissue markers and uses thereof
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
US10874921B2 (en) * 2014-02-20 2020-12-29 Parsons Xtreme Golf, LLC Golf club heads and methods to manufacture golf club heads
US9909999B2 (en) 2015-03-27 2018-03-06 Delavan Inc. Systems and methods for radiographic inspection
US10071181B1 (en) 2015-04-17 2018-09-11 Teleflex Innovations S.À.R.L. Resorbable embolization spheres
WO2019159062A1 (en) * 2018-02-13 2019-08-22 Murphy Kieran P Delivery system for delivering a drug depot to a target site under image guidance and methods and uses of same

Citations (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581235A (en) 1897-04-20 Island
US1578517A (en) 1924-12-23 1926-03-30 George N Hein Valve piston and barrel construction for hypodermic syringes
US2086580A (en) 1935-06-24 1937-07-13 Myron C Shirley Applicator
US2370319A (en) 1944-11-07 1945-02-27 Dohner & Lippincott Paper perforator
US2465357A (en) 1944-08-14 1949-03-29 Upjohn Co Therapeutic sponge and method of making
US2492458A (en) 1944-12-08 1949-12-27 Jr Edgar A Bering Fibrin foam
US2507244A (en) 1947-04-14 1950-05-09 Upjohn Co Surgical gelatin dusting powder and process for preparing same
US2558395A (en) 1947-06-03 1951-06-26 Hoffmann La Roche Undenatured gelatin hemostatic sponge containing thrombin
US2597011A (en) 1950-07-28 1952-05-20 Us Agriculture Preparation of starch sponge
US2680442A (en) 1952-04-04 1954-06-08 Frank L Linzmayer Disposable suppository casing
US2761446A (en) 1955-03-30 1956-09-04 Chemical Specialties Co Inc Implanter and cartridge
US2814294A (en) 1953-04-17 1957-11-26 Becton Dickinson Co Unit for and method of inhibiting and controlling bleeding tendencies
US2824092A (en) 1955-01-04 1958-02-18 Robert E Thompson Process of preparation of a gelatincarboxymethyl cellulose complex
US2874776A (en) 1954-06-07 1959-02-24 Royal Mcbee Corp Punch and die mechanism
US2899362A (en) 1959-08-11 Hemostatic sponges and method of
US2997195A (en) 1959-07-16 1961-08-22 Yuen Yat Chuen Drinking straws
US3157524A (en) 1960-10-25 1964-11-17 Ethicon Inc Preparation of collagen sponge
US3358689A (en) 1964-06-09 1967-12-19 Roehr Products Company Inc Integral lancet and package
US3411505A (en) 1965-12-15 1968-11-19 Paul D. Nobis Device for interrupting arterial flow
US3703174A (en) 1970-07-14 1972-11-21 Medidyne Corp Method and apparatus for catheter injection
US3724465A (en) 1971-07-22 1973-04-03 Kimberly Clark Co Tampon coated with insertion aid and method for coating
US3736939A (en) 1972-01-07 1973-06-05 Kendall & Co Balloon catheter with soluble tip
US4000741A (en) 1975-11-03 1977-01-04 The Kendall Company Syringe assembly
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4211323A (en) 1978-12-01 1980-07-08 California Medical Developments, Inc. Disposable diagnostic swab having a stored culture medium
US4218155A (en) 1978-02-10 1980-08-19 Etablissements Armor, S.A. Stick for applying a liquid
US4219026A (en) 1978-09-15 1980-08-26 The Kendall Company Bladder hemostatic catheter
US4224945A (en) 1978-08-30 1980-09-30 Jonathan Cohen Inflatable expansible surgical pressure dressing
US4238480A (en) 1978-05-19 1980-12-09 Sawyer Philip Nicholas Method for preparing an improved hemostatic agent and method of employing the same
US4292972A (en) 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4323072A (en) 1980-01-18 1982-04-06 Shiley, Incorporated Cannula for a vein distention system
US4340066A (en) 1980-02-01 1982-07-20 Sherwood Medical Industries Inc. Medical device for collecting a body sample
US4390018A (en) 1980-09-15 1983-06-28 Zukowski Henry J Method for preventing loss of spinal fluid after spinal tap
US4405314A (en) 1982-04-19 1983-09-20 Cook Incorporated Apparatus and method for catheterization permitting use of a smaller gage needle
US4404970A (en) 1978-05-19 1983-09-20 Sawyer Philip Nicholas Hemostatic article and methods for preparing and employing the same
US4515637A (en) 1983-11-16 1985-05-07 Seton Company Collagen-thrombin compositions
US4573576A (en) 1983-10-27 1986-03-04 Krol Thomas C Percutaneous gastrostomy kit
US4587969A (en) 1985-01-28 1986-05-13 Rolando Gillis Support assembly for a blood vessel or like organ
US4588395A (en) 1978-03-10 1986-05-13 Lemelson Jerome H Catheter and method
US4591094A (en) 1983-08-13 1986-05-27 Arthur Morris Fountain
US4619913A (en) 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4619261A (en) 1984-08-09 1986-10-28 Frederico Guerriero Hydrostatic pressure device for bleeding control through an inflatable, stitchable and retrievable balloon-net system
US4644649A (en) 1985-09-26 1987-02-24 Seaman Roy C Apparatus for trimming reeds of musical instruments
US4645488A (en) 1982-08-12 1987-02-24 Board Of Trustees Of The University Of Alabama Syringe for extrusion of wetted, particulate material
US4699616A (en) 1986-06-13 1987-10-13 Hollister Incorporated Catheter retention device and method
US4708718A (en) 1985-07-02 1987-11-24 Target Therapeutics Hyperthermic treatment of tumors
US4744364A (en) 1987-02-17 1988-05-17 Intravascular Surgical Instruments, Inc. Device for sealing percutaneous puncture in a vessel
US4790819A (en) 1987-08-24 1988-12-13 American Cyanamid Company Fibrin clot delivery device and method
US4829994A (en) 1987-05-27 1989-05-16 Kurth Paul A Femoral compression device for post-catheterization hemostasis
US4832688A (en) 1986-04-09 1989-05-23 Terumo Kabushiki Kaisha Catheter for repair of blood vessel
US4836204A (en) 1987-07-06 1989-06-06 Landymore Roderick W Method for effecting closure of a perforation in the septum of the heart
US4839204A (en) 1987-05-19 1989-06-13 Yazaki Kakoh Co., Ltd. Resin coated metal pipe having a plane surface for a lightweight structure
US4850960A (en) 1987-07-08 1989-07-25 Joseph Grayzel Diagonally tapered, bevelled tip introducing catheter and sheath and method for insertion
US4852568A (en) 1987-02-17 1989-08-01 Kensey Nash Corporation Method and apparatus for sealing an opening in tissue of a living being
US4869143A (en) 1985-06-11 1989-09-26 Merrick Industries, Inc. Card file punch
US4890612A (en) 1987-02-17 1990-01-02 Kensey Nash Corporation Device for sealing percutaneous puncture in a vessel
US4900303A (en) 1978-03-10 1990-02-13 Lemelson Jerome H Dispensing catheter and method
US4929246A (en) 1988-10-27 1990-05-29 C. R. Bard, Inc. Method for closing and sealing an artery after removing a catheter
US4936835A (en) 1988-05-26 1990-06-26 Haaga John R Medical needle with bioabsorbable tip
US4950234A (en) 1987-05-26 1990-08-21 Sumitomo Pharmaceuticals Company, Limited Device for administering solid preparations
US5007895A (en) 1989-04-05 1991-04-16 Burnett George S Wound packing instrument
US5021059A (en) 1990-05-07 1991-06-04 Kensey Nash Corporation Plug device with pulley for sealing punctures in tissue and methods of use
US5049138A (en) 1989-11-13 1991-09-17 Boston Scientific Corporation Catheter with dissolvable tip
US5053046A (en) 1988-08-22 1991-10-01 Woodrow W. Janese Dural sealing needle and method of use
US5061274A (en) 1989-12-04 1991-10-29 Kensey Nash Corporation Plug device for sealing openings and method of use
US5080655A (en) 1988-05-26 1992-01-14 Haaga John R Medical biopsy needle
US5106376A (en) 1989-07-07 1992-04-21 B. Braun Melsungen Ag Anaesthesia set
US5108421A (en) 1990-10-01 1992-04-28 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
US5129889A (en) 1987-11-03 1992-07-14 Hahn John L Synthetic absorbable epidural catheter
US5160323A (en) 1989-05-26 1992-11-03 Andrew Daniel E Method and system for inserting spinal catheters
US5163904A (en) 1991-11-12 1992-11-17 Merit Medical Systems, Inc. Syringe apparatus with attached pressure gauge
US5167624A (en) 1990-11-09 1992-12-01 Catheter Research, Inc. Embolus delivery system and method
US5192300A (en) 1990-10-01 1993-03-09 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
US5192290A (en) 1990-08-29 1993-03-09 Applied Medical Resources, Inc. Embolectomy catheter
US5192301A (en) 1989-01-17 1993-03-09 Nippon Zeon Co., Ltd. Closing plug of a defect for medical use and a closing plug device utilizing it
US5195988A (en) 1988-05-26 1993-03-23 Haaga John R Medical needle with removable sheath
US5219899A (en) 1989-04-22 1993-06-15 Degussa Aktiengesellschaft Pasty dental material which is an organopolysilane filler combined with a polymerizable bonding agent
US5220926A (en) 1992-07-13 1993-06-22 Jones George T Finger mounted core biopsy guide
US5221259A (en) 1990-12-27 1993-06-22 Novoste Corporation Wound treating device and method of using same
US5232453A (en) 1989-07-14 1993-08-03 E. R. Squibb & Sons, Inc. Catheter holder
US5242683A (en) 1989-07-21 1993-09-07 Nycomed Imaging As Contrast media comprising a paramagnetic agent and an iodinated agent for x-ray and mri
US5254105A (en) 1988-05-26 1993-10-19 Haaga John R Sheath for wound closure caused by a medical tubular device
US5282827A (en) 1991-11-08 1994-02-01 Kensey Nash Corporation Hemostatic puncture closure system and method of use
US5299581A (en) 1990-07-05 1994-04-05 Donnell John T Intravaginal device
US5310407A (en) 1991-06-17 1994-05-10 Datascope Investment Corp. Laparoscopic hemostat delivery system and method for using said system
US5320639A (en) 1993-03-12 1994-06-14 Meadox Medicals, Inc. Vascular plug delivery system
US5322515A (en) 1993-03-15 1994-06-21 Abbott Laboratories Luer adapter assembly for emergency syringe
US5325857A (en) 1993-07-09 1994-07-05 Hossein Nabai Skin biopsy device and method
US5334216A (en) 1992-12-10 1994-08-02 Howmedica Inc. Hemostatic plug
US5342388A (en) 1993-03-25 1994-08-30 Sonia Toller Method and apparatus for sealing luminal tissue
US5350399A (en) 1991-09-23 1994-09-27 Jay Erlebacher Percutaneous arterial puncture seal device and insertion tool therefore
US5352211A (en) 1993-07-11 1994-10-04 Louisville Laboratories External stability device
US5366480A (en) 1990-12-24 1994-11-22 American Cyanamid Company Synthetic elastomeric buttressing pledget
US5370656A (en) 1993-02-26 1994-12-06 Merocel Corporation Throat pack
US5383899A (en) 1993-09-28 1995-01-24 Hammerslag; Julius G. Method of using a surface opening adhesive sealer
US5383896A (en) 1993-05-25 1995-01-24 Gershony; Gary Vascular sealing device
US5385550A (en) 1994-03-29 1995-01-31 Su; Chan-Ho Needle protective means for prevention against stab and virus infection
US5388588A (en) 1993-05-04 1995-02-14 Nabai; Hossein Biopsy wound closure device and method

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US451094A (en) * 1891-04-28 Sectional steam-generator
US3874388A (en) 1973-02-12 1975-04-01 Ochsner Med Found Alton Shunt defect closure system
SE7608618L (en) 1976-07-30 1978-02-01 Medline Ab CLOSURE OF CHANNELS
SU782814A1 (en) 1977-01-18 1980-11-30 За витель Prosthesis for closing defect in heart tissues
SU1088709A1 (en) 1981-02-10 1984-04-30 Институт Клинической И Экспериментальной Хирургии Method of treatment of stomach fistula
JPS6144825A (en) * 1984-08-09 1986-03-04 Unitika Ltd Hemostatic agent
US4573573A (en) * 1985-01-02 1986-03-04 Lori Favaro Protective covering for portable audio devices
US5620461A (en) * 1989-05-29 1997-04-15 Muijs Van De Moer; Wouter M. Sealing device
DE476178T1 (en) 1990-09-21 1992-07-23 Bioplex Medical B.V., Vaals, Nl DEVICE FOR THE APPLICATION OF ANTI-BLOODING FABRIC ON PERFORATED BLOOD VESSELS.
US5391183A (en) 1990-09-21 1995-02-21 Datascope Investment Corp Device and method sealing puncture wounds
US5419765A (en) 1990-12-27 1995-05-30 Novoste Corporation Wound treating device and method for treating wounds
JP3356447B2 (en) * 1991-10-16 2002-12-16 テルモ株式会社 Vascular lesion embolic material composed of dried polymer gel
US5676689A (en) * 1991-11-08 1997-10-14 Kensey Nash Corporation Hemostatic puncture closure system including vessel location device and method of use
US5433725A (en) * 1991-12-13 1995-07-18 Unisurge, Inc. Hand-held surgical device and tools for use therewith, assembly and method
US6056768A (en) * 1992-01-07 2000-05-02 Cates; Christopher U. Blood vessel sealing system
IL105529A0 (en) * 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins
US5326350A (en) * 1992-05-11 1994-07-05 Li Shu Tung Soft tissue closure systems
US5413571A (en) 1992-07-16 1995-05-09 Sherwood Medical Company Device for sealing hemostatic incisions
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5417699A (en) * 1992-12-10 1995-05-23 Perclose Incorporated Device and method for the percutaneous suturing of a vascular puncture site
DE69323975T2 (en) * 1992-12-15 1999-08-19 Johnson & Johnson Consumer Hydrogel laminate, wound dressings and composite materials and processes for their manufacture
SK281535B6 (en) 1993-01-25 2001-04-09 Sonus Pharmaceuticals, Inc. Contrast medium for diagnostic ultrasound procedures and process for preparing thereof
DE59400518D1 (en) * 1993-06-16 1996-09-26 White Spot Ag DEVICE FOR PUTTING FIBRINE ADHESIVE INTO A STITCH CHANNEL
US5486195A (en) 1993-07-26 1996-01-23 Myers; Gene Method and apparatus for arteriotomy closure
US5431639A (en) 1993-08-12 1995-07-11 Boston Scientific Corporation Treating wounds caused by medical procedures
US5653730A (en) 1993-09-28 1997-08-05 Hemodynamics, Inc. Surface opening adhesive sealer
AU1086795A (en) * 1993-11-03 1995-05-23 Clarion Pharmaceuticals, Inc. Hemostatic patch
US5507279A (en) * 1993-11-30 1996-04-16 Fortune; John B. Retrograde endotracheal intubation kit
US5649547A (en) 1994-03-24 1997-07-22 Biopsys Medical, Inc. Methods and devices for automated biopsy and collection of soft tissue
US5526822A (en) 1994-03-24 1996-06-18 Biopsys Medical, Inc. Method and apparatus for automated biopsy and collection of soft tissue
US5545178A (en) 1994-04-29 1996-08-13 Kensey Nash Corporation System for closing a percutaneous puncture formed by a trocar to prevent tissue at the puncture from herniating
US5522850A (en) 1994-06-23 1996-06-04 Incontrol, Inc. Defibrillation and method for cardioverting a heart and storing related activity data
DE19580865D2 (en) * 1994-08-17 1998-03-19 Boston Scient Corp Implant, implantation method and application device
US5931165A (en) * 1994-09-06 1999-08-03 Fusion Medical Technologies, Inc. Films having improved characteristics and methods for their preparation and use
US5490736A (en) * 1994-09-08 1996-02-13 Habley Medical Technology Corporation Stylus applicator for a rehydrated multi-constituent medication
JPH10508504A (en) 1994-09-16 1998-08-25 バイオプシス メディカル インコーポレイテッド Method and apparatus for identifying and marking tissue
US5624402A (en) * 1994-12-12 1997-04-29 Becton, Dickinson And Company Syringe tip cap
JPH10512470A (en) * 1995-01-18 1998-12-02 メドケム プロダクツ,インコーポレーテッド Apparatus and method for applying a hemostatic agent to tissue
US6071301A (en) * 1998-05-01 2000-06-06 Sub Q., Inc. Device and method for facilitating hemostasis of a biopsy tract
US6162192A (en) * 1998-05-01 2000-12-19 Sub Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6071300A (en) * 1995-09-15 2000-06-06 Sub-Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US5645566A (en) 1995-09-15 1997-07-08 Sub Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US6183497B1 (en) * 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
US5769086A (en) 1995-12-06 1998-06-23 Biopsys Medical, Inc. Control system and method for automated biopsy device
US5800389A (en) * 1996-02-09 1998-09-01 Emx, Inc. Biopsy device
US5601207A (en) * 1996-03-13 1997-02-11 Paczonay; Joseph R. Bite valve having a plurality of slits
US5827218A (en) * 1996-04-18 1998-10-27 Stryker Corporation Surgical suction pool tip
US5858008A (en) * 1997-04-22 1999-01-12 Becton, Dickinson And Company Cannula sealing shield assembly
US5902310A (en) 1996-08-12 1999-05-11 Ethicon Endo-Surgery, Inc. Apparatus and method for marking tissue
US6066325A (en) * 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6706690B2 (en) * 1999-06-10 2004-03-16 Baxter Healthcare Corporation Hemoactive compositions and methods for their manufacture and use
US5810806A (en) 1996-08-29 1998-09-22 Ethicon Endo-Surgery Methods and devices for collection of soft tissue
US5681279A (en) 1996-11-04 1997-10-28 Roper; David H. Pill dispensing syringe
US5782861A (en) * 1996-12-23 1998-07-21 Sub Q Inc. Percutaneous hemostasis device
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US5868762A (en) * 1997-09-25 1999-02-09 Sub-Q, Inc. Percutaneous hemostatic suturing device and method
US6033427A (en) * 1998-01-07 2000-03-07 Lee; Benjamin I. Method and device for percutaneous sealing of internal puncture sites
US6161034A (en) * 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6315753B1 (en) * 1998-05-01 2001-11-13 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6200328B1 (en) * 1998-05-01 2001-03-13 Sub Q, Incorporated Device and method for facilitating hemostasis of a biopsy tract
US20010045575A1 (en) * 1998-05-01 2001-11-29 Mark Ashby Device and method for facilitating hemostasis of a biopsy tract
US6126675A (en) * 1999-01-11 2000-10-03 Ethicon, Inc. Bioabsorbable device and method for sealing vascular punctures
JP4271375B2 (en) * 1999-02-10 2009-06-03 サブ−キュー・インコーポレーテッド Device and method for facilitating hemostasis in a biopsy duct
US6984219B2 (en) * 1999-09-23 2006-01-10 Mark Ashby Depth and puncture control for blood vessel hemostasis system
US6547806B1 (en) * 2000-02-04 2003-04-15 Ni Ding Vascular sealing device and method of use
AU2001255725A1 (en) * 2000-04-28 2001-11-12 Sub-Q Inc. Easy cutter
US6540735B1 (en) * 2000-05-12 2003-04-01 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6503222B2 (en) * 2000-09-28 2003-01-07 Pfizer Inc Oral dosage dispenser
US8187625B2 (en) * 2001-03-12 2012-05-29 Boston Scientific Scimed, Inc. Cross-linked gelatin composition comprising a wetting agent
US6863680B2 (en) * 2001-11-08 2005-03-08 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7008440B2 (en) * 2001-11-08 2006-03-07 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7025748B2 (en) * 2001-11-08 2006-04-11 Boston Scientific Scimed, Inc. Sheath based blood vessel puncture locator and depth indicator

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899362A (en) 1959-08-11 Hemostatic sponges and method of
US581235A (en) 1897-04-20 Island
US1578517A (en) 1924-12-23 1926-03-30 George N Hein Valve piston and barrel construction for hypodermic syringes
US2086580A (en) 1935-06-24 1937-07-13 Myron C Shirley Applicator
US2465357A (en) 1944-08-14 1949-03-29 Upjohn Co Therapeutic sponge and method of making
US2370319A (en) 1944-11-07 1945-02-27 Dohner & Lippincott Paper perforator
US2492458A (en) 1944-12-08 1949-12-27 Jr Edgar A Bering Fibrin foam
US2507244A (en) 1947-04-14 1950-05-09 Upjohn Co Surgical gelatin dusting powder and process for preparing same
US2558395A (en) 1947-06-03 1951-06-26 Hoffmann La Roche Undenatured gelatin hemostatic sponge containing thrombin
US2597011A (en) 1950-07-28 1952-05-20 Us Agriculture Preparation of starch sponge
US2680442A (en) 1952-04-04 1954-06-08 Frank L Linzmayer Disposable suppository casing
US2814294A (en) 1953-04-17 1957-11-26 Becton Dickinson Co Unit for and method of inhibiting and controlling bleeding tendencies
US2874776A (en) 1954-06-07 1959-02-24 Royal Mcbee Corp Punch and die mechanism
US2824092A (en) 1955-01-04 1958-02-18 Robert E Thompson Process of preparation of a gelatincarboxymethyl cellulose complex
US2761446A (en) 1955-03-30 1956-09-04 Chemical Specialties Co Inc Implanter and cartridge
US2997195A (en) 1959-07-16 1961-08-22 Yuen Yat Chuen Drinking straws
US3157524A (en) 1960-10-25 1964-11-17 Ethicon Inc Preparation of collagen sponge
US3358689A (en) 1964-06-09 1967-12-19 Roehr Products Company Inc Integral lancet and package
US3411505A (en) 1965-12-15 1968-11-19 Paul D. Nobis Device for interrupting arterial flow
US3703174A (en) 1970-07-14 1972-11-21 Medidyne Corp Method and apparatus for catheter injection
US3724465A (en) 1971-07-22 1973-04-03 Kimberly Clark Co Tampon coated with insertion aid and method for coating
US3736939A (en) 1972-01-07 1973-06-05 Kendall & Co Balloon catheter with soluble tip
US4000741A (en) 1975-11-03 1977-01-04 The Kendall Company Syringe assembly
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4218155A (en) 1978-02-10 1980-08-19 Etablissements Armor, S.A. Stick for applying a liquid
US4900303A (en) 1978-03-10 1990-02-13 Lemelson Jerome H Dispensing catheter and method
US4588395A (en) 1978-03-10 1986-05-13 Lemelson Jerome H Catheter and method
US4404970A (en) 1978-05-19 1983-09-20 Sawyer Philip Nicholas Hemostatic article and methods for preparing and employing the same
US4238480A (en) 1978-05-19 1980-12-09 Sawyer Philip Nicholas Method for preparing an improved hemostatic agent and method of employing the same
US4224945A (en) 1978-08-30 1980-09-30 Jonathan Cohen Inflatable expansible surgical pressure dressing
US4219026A (en) 1978-09-15 1980-08-26 The Kendall Company Bladder hemostatic catheter
US4211323A (en) 1978-12-01 1980-07-08 California Medical Developments, Inc. Disposable diagnostic swab having a stored culture medium
US4323072A (en) 1980-01-18 1982-04-06 Shiley, Incorporated Cannula for a vein distention system
US4340066A (en) 1980-02-01 1982-07-20 Sherwood Medical Industries Inc. Medical device for collecting a body sample
US4292972A (en) 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4390018A (en) 1980-09-15 1983-06-28 Zukowski Henry J Method for preventing loss of spinal fluid after spinal tap
US4405314A (en) 1982-04-19 1983-09-20 Cook Incorporated Apparatus and method for catheterization permitting use of a smaller gage needle
US4645488A (en) 1982-08-12 1987-02-24 Board Of Trustees Of The University Of Alabama Syringe for extrusion of wetted, particulate material
US4591094A (en) 1983-08-13 1986-05-27 Arthur Morris Fountain
US4573576A (en) 1983-10-27 1986-03-04 Krol Thomas C Percutaneous gastrostomy kit
US4515637A (en) 1983-11-16 1985-05-07 Seton Company Collagen-thrombin compositions
US4619913A (en) 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4619261A (en) 1984-08-09 1986-10-28 Frederico Guerriero Hydrostatic pressure device for bleeding control through an inflatable, stitchable and retrievable balloon-net system
US4587969A (en) 1985-01-28 1986-05-13 Rolando Gillis Support assembly for a blood vessel or like organ
US4869143A (en) 1985-06-11 1989-09-26 Merrick Industries, Inc. Card file punch
US4708718A (en) 1985-07-02 1987-11-24 Target Therapeutics Hyperthermic treatment of tumors
US4644649A (en) 1985-09-26 1987-02-24 Seaman Roy C Apparatus for trimming reeds of musical instruments
US4832688A (en) 1986-04-09 1989-05-23 Terumo Kabushiki Kaisha Catheter for repair of blood vessel
US4699616A (en) 1986-06-13 1987-10-13 Hollister Incorporated Catheter retention device and method
US4744364A (en) 1987-02-17 1988-05-17 Intravascular Surgical Instruments, Inc. Device for sealing percutaneous puncture in a vessel
US4852568A (en) 1987-02-17 1989-08-01 Kensey Nash Corporation Method and apparatus for sealing an opening in tissue of a living being
US4890612A (en) 1987-02-17 1990-01-02 Kensey Nash Corporation Device for sealing percutaneous puncture in a vessel
US4839204A (en) 1987-05-19 1989-06-13 Yazaki Kakoh Co., Ltd. Resin coated metal pipe having a plane surface for a lightweight structure
US4950234A (en) 1987-05-26 1990-08-21 Sumitomo Pharmaceuticals Company, Limited Device for administering solid preparations
US4829994A (en) 1987-05-27 1989-05-16 Kurth Paul A Femoral compression device for post-catheterization hemostasis
US4836204A (en) 1987-07-06 1989-06-06 Landymore Roderick W Method for effecting closure of a perforation in the septum of the heart
US4850960A (en) 1987-07-08 1989-07-25 Joseph Grayzel Diagonally tapered, bevelled tip introducing catheter and sheath and method for insertion
US4790819A (en) 1987-08-24 1988-12-13 American Cyanamid Company Fibrin clot delivery device and method
US5129889A (en) 1987-11-03 1992-07-14 Hahn John L Synthetic absorbable epidural catheter
US4936835A (en) 1988-05-26 1990-06-26 Haaga John R Medical needle with bioabsorbable tip
US5254105A (en) 1988-05-26 1993-10-19 Haaga John R Sheath for wound closure caused by a medical tubular device
US5195988A (en) 1988-05-26 1993-03-23 Haaga John R Medical needle with removable sheath
US5080655A (en) 1988-05-26 1992-01-14 Haaga John R Medical biopsy needle
US5053046A (en) 1988-08-22 1991-10-01 Woodrow W. Janese Dural sealing needle and method of use
US4929246A (en) 1988-10-27 1990-05-29 C. R. Bard, Inc. Method for closing and sealing an artery after removing a catheter
US5192301A (en) 1989-01-17 1993-03-09 Nippon Zeon Co., Ltd. Closing plug of a defect for medical use and a closing plug device utilizing it
US5007895A (en) 1989-04-05 1991-04-16 Burnett George S Wound packing instrument
US5219899A (en) 1989-04-22 1993-06-15 Degussa Aktiengesellschaft Pasty dental material which is an organopolysilane filler combined with a polymerizable bonding agent
US5160323A (en) 1989-05-26 1992-11-03 Andrew Daniel E Method and system for inserting spinal catheters
US5106376A (en) 1989-07-07 1992-04-21 B. Braun Melsungen Ag Anaesthesia set
US5232453A (en) 1989-07-14 1993-08-03 E. R. Squibb & Sons, Inc. Catheter holder
US5242683A (en) 1989-07-21 1993-09-07 Nycomed Imaging As Contrast media comprising a paramagnetic agent and an iodinated agent for x-ray and mri
US5049138A (en) 1989-11-13 1991-09-17 Boston Scientific Corporation Catheter with dissolvable tip
US5061274A (en) 1989-12-04 1991-10-29 Kensey Nash Corporation Plug device for sealing openings and method of use
US5021059A (en) 1990-05-07 1991-06-04 Kensey Nash Corporation Plug device with pulley for sealing punctures in tissue and methods of use
US5299581A (en) 1990-07-05 1994-04-05 Donnell John T Intravaginal device
US5192290A (en) 1990-08-29 1993-03-09 Applied Medical Resources, Inc. Embolectomy catheter
US5275616A (en) 1990-10-01 1994-01-04 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
US5192300A (en) 1990-10-01 1993-03-09 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
US5275616B1 (en) 1990-10-01 1996-01-23 Quinton Instr Insertion assembly and method of inserting a vessel plug into the body of a patient
US5108421A (en) 1990-10-01 1992-04-28 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
US5167624A (en) 1990-11-09 1992-12-01 Catheter Research, Inc. Embolus delivery system and method
US5366480A (en) 1990-12-24 1994-11-22 American Cyanamid Company Synthetic elastomeric buttressing pledget
US5221259A (en) 1990-12-27 1993-06-22 Novoste Corporation Wound treating device and method of using same
US5310407A (en) 1991-06-17 1994-05-10 Datascope Investment Corp. Laparoscopic hemostat delivery system and method for using said system
US5350399A (en) 1991-09-23 1994-09-27 Jay Erlebacher Percutaneous arterial puncture seal device and insertion tool therefore
US5282827A (en) 1991-11-08 1994-02-01 Kensey Nash Corporation Hemostatic puncture closure system and method of use
US5163904A (en) 1991-11-12 1992-11-17 Merit Medical Systems, Inc. Syringe apparatus with attached pressure gauge
US5220926A (en) 1992-07-13 1993-06-22 Jones George T Finger mounted core biopsy guide
US5334216A (en) 1992-12-10 1994-08-02 Howmedica Inc. Hemostatic plug
US5370656A (en) 1993-02-26 1994-12-06 Merocel Corporation Throat pack
US5320639A (en) 1993-03-12 1994-06-14 Meadox Medicals, Inc. Vascular plug delivery system
US5322515A (en) 1993-03-15 1994-06-21 Abbott Laboratories Luer adapter assembly for emergency syringe
US5342388A (en) 1993-03-25 1994-08-30 Sonia Toller Method and apparatus for sealing luminal tissue
US5388588A (en) 1993-05-04 1995-02-14 Nabai; Hossein Biopsy wound closure device and method
US5383896A (en) 1993-05-25 1995-01-24 Gershony; Gary Vascular sealing device
US5325857A (en) 1993-07-09 1994-07-05 Hossein Nabai Skin biopsy device and method
US5352211A (en) 1993-07-11 1994-10-04 Louisville Laboratories External stability device
US5383899A (en) 1993-09-28 1995-01-24 Hammerslag; Julius G. Method of using a surface opening adhesive sealer
US5385550A (en) 1994-03-29 1995-01-31 Su; Chan-Ho Needle protective means for prevention against stab and virus infection

Non-Patent Citations (45)

* Cited by examiner, † Cited by third party
Title
"Gelfoam Sterile Powder," Pharmacia & Upjohn Manufacturer Brochure, Feb. 1996.
"Gelfoam Sterile Powder," Pharmacia & Upjohn Manufacturer Brochure, Mar. 1996.
"Gelfoam Sterile Sponge, Sterile Powder and Sterile Film," Pharmacia & Upjohn Manufacturer Brochure, May 1997, p. 1.
"Gelfoam Sterile Sponge, Sterile Powder and Sterile Film," Pharmacia & Upjohn Manufacturer Specification, Nov. 1996, p. 1.
(130) Ashby, Mark et al; U.S. Appl. No. 10/069,107, filed Dec. 16, 2002; entitled: Device And Method For Determining A Depth Of An Incision.
(144) Ashby, Mark et al; U.S. Appl. No. 10/278,710, filed Oct. 22, 2002; entitled: "System and Method for Facilitating Hemostasis of Blood Vessel Punctures With Absorbable Sponge".
(152) Ashby, Mark et al; U.S. Appl. No. 10/334,770, filed Dec 31, 2002; entitled: "Improved System and Method for Facilitating Hemostasis with Absorbable Sponge".
(154) Ashby, Mark et al; U.S. Appl. No. 10/421,680, filed Apr. 22, 2003; entitled: "Puncture Closure System With Pin and Pull Technique".
(159) Ashby, Mark et al; U.S. Appl. No. 10/462,065, filed Jun. 12, 2003; entitled: "Enhanced Bleed Back System".
(160) Ashby, Mark et al, U.S. Appl. No. 10/462,064, filed Jun. 12, 2003; entitled: "Release Mechanism".
(161) Ashby, Mark et al; U.S. Appl. No. 10/461,587, filed Jun. 12, 2003; entitled: "Dissolvable Closure Device".
(162) Ashby, Mark et al; U.S. Appl. No. 10/461,035, filed Jun. 13,2003; entitled: "System And Method For Delivering Hemostasis Promoting Material to A Blood Vessel Puncture Site Using a Cannula".
(163) Ashby, Mark et al; U.S. Appl. No. 10/461,006, filed Jun. 13, 2003; entitled: "System and Method for Delivering Hemostasis Promoting Material to a Blood Vessel Puncture with a Staging Tube".
(164) Ashby, Mark et al; U.S. Appl. No. 10/460,859, filed Jun. 12, 2003; entitled: "Hemostatic Device Including a Capsule".
(187) Ashby, Mark et al; U.S. Appl. No. 10/732,441, filed Dec. 9, 2003; entitled: "Pledget-Handling System and Method for Delivering Hemostasis Promoting Material to a Blood Vessel Puncture Site by Fluid Pressure".
(190) Ashby, Mark et al; U.S. Appl. No. 10/754,824, filed Jan. 9,2004; entitled: "Sheath-Mounted Arterial Plug Delivery Device".
Allison, D., "Percutaneous Liver Biopsy and Track Embolization with Steel Coils," Radiology, vol. 169, 1998, p. 261.
Berman, Howard L., "Guided Direct Antegrade Puncture of the Superficial Femoral Artry," American Ray Society Roentgen, Sep. 1986, p. 632.
Berman, Howard L., "Modification of the Cope Drainage Catheter to Facilitate Placement," American Ray Society Roentgen, Jan. 1986, pp. 146, 169.
Bryne, J., "Endovascular Treatments for Intracranial Anuerysms," The British Journal of Radiology, 1996, pp. 98, 891.
Chuang, V., "Sheath Needle for Liver Biopsy in High-Risk Patience," Radiology, vol. 166, 1988, p. 261.
Correll, John T., "Biologic Investigations of New Absorbable Sponge," Research Laboratories of the Upjohn Company, 1945, p. 585.
Correll, John T., "Certain Properties of a New Physiologically Absorbable Sponge, " Research Laboratories of the Upjohn Company, 1944, p. 233.
Di Seni, Ricardo, "Part 1, Embolotherapy: Agents, Equipment, and Techniques," Vascular Embolotherapy, vol. 4, p. 29.
Fandrich, C., "Small Guage Gelfoam Plug Liver Biopsy in High Risk Patients," Australian Radiology, vol. 40, 1996, p. 230. High Risk Patients, Australian Radiology, vol. 40, 1996, p. 230.
Foran, JPM, "Early Mobilization After Percutaneous Cardiac Catheterisation Using Collagen Plug (Vasoseal) Maemostatis," BRHeart, vol. 69, 1993, p. 424.
Gibbs, JSR, "Femoral Arterial Hemostasis Using a Collagen Plug After Coronary Artery Stent Implantation," J. Interventional Card, vol. 5, 1992, p. 85.
Journal of Interventional Cardiology, vol. 5, No. 2, Jun. 1992.
Kassell, "Size of Intracanial Aneurysm," vol. 12, No. 3, 1983.
Kiemeneiji, F., "Improved Anticoagulation Management after Palmaz Schatz Coronary Stent Implantation by Sealing the Arterial Puncture Site with Vascular Hemostasis Device," Catheterization and Cardiovascular Diagnosis, vol. 30, 1995, p. 1685.
Kussmaul, WG, "Rapid Arterial Hemostasis . . . Randomized Trial of a Novel Hemostatic Device," J. Am. Coll. Card., vol. 25, 1995, p. 1685.
Our Pending Applications (125) Ashby, Mark et al; U.S. Appl. No. 10/287,922, filed Nov. 4, 2002; entitled: Apparatus And Method For Inhibiting Blood Loss.
Riley, SA, "Percutaneous Liver Biopsy with Plugging of Needle Track: a Safe Method for Use in Patients with Impaired Coagulation," The Lancet, 1964, p. 436.
Saddekni, S., M.D., "Antegrade Cathererization of the Superficial Femoral Artery," Radiology, 1985, p. 531.
Sanborn, T., "Multicenter Randomized Trial Comparing Perutaneous Collagen Hemostasis Device with Conventional Manual Compression after Diagnostic Angiography and Angioplasty," J. Am. Coll. Card., vol. 22, 1993, p. 1273.
Scharader, R., "Collagen Appl.," Catheterization & Cardiovascular Diagnosis, 1992, p. 298.
Schievink, "Intracanial Aneurysms," The New England Journal of Medicine; Review Articles, Jan. 2, 1997.
Silber, S., "Rapid Hemostasis of Arterial Puncture Sites with Collagen in Patients Undergoing Diagnostic Interventional Cardiac Catherterization," Clinical Cardiology, vol. 20, 1997, p. 981.
Smith, T., "Percutaneous Transhepatic Liver Biopsy with Tract Embolization," Radiology, vol. 198, 1996, p. 769.
Szikora, "Combined Use of Stents and Cells to Treat Experimental Wide-Necked Carotid Aneuryms: Preliminary Results," AJNR AM Newradiol, Jun. 1994, p. 1091.
Szikora, "Endovascular Treatment of Experimental Anuerysms with Liquid Polymers," vol. 38, No. 2, Feb. 1996.
Turjman, "Combined Stent Implantation & Endosacular Coil Placement for Treatment of Experimental Wide-Necked Aneurysms," AJNRAM J. Neuroradio, Jun. 1994, p. 1087.
Vogelzang, Robert L., "A Modified Cope Introducing Dilator to Allow Straight Guide Wire Introduction," American Roantigen Ray Society, Feb. 1986, p. 381.
Yoshimoto, "Cerebral Anuerysms Unrelated to Arterial Bifurcations," Acta Neurochir (Wien), 1996, pp. 138, 958.
Zins, M., "US-Guided Percutaneous Liver Biopsy with Plugging of the Needle Track," Radiology, vol. 187, 1992, p. 841..

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642658B2 (en) 2008-10-15 2017-05-09 Orthoclip Llc Device and method for delivery of therapeutic agents via internal implants
US10643371B2 (en) 2014-08-11 2020-05-05 Covidien Lp Treatment procedure planning system and method
US11227427B2 (en) 2014-08-11 2022-01-18 Covidien Lp Treatment procedure planning system and method
US11238642B2 (en) 2014-08-11 2022-02-01 Covidien Lp Treatment procedure planning system and method
US11769292B2 (en) 2014-08-11 2023-09-26 Covidien Lp Treatment procedure planning system and method

Also Published As

Publication number Publication date
EP1191884A1 (en) 2002-04-03
AU5877200A (en) 2001-01-09
US20100029908A1 (en) 2010-02-04
WO2000078228A9 (en) 2002-09-26
US20050059080A1 (en) 2005-03-17
US6183497B1 (en) 2001-02-06
US20130172737A1 (en) 2013-07-04
JP2003502099A (en) 2003-01-21
US20020038133A1 (en) 2002-03-28
WO2000078228A1 (en) 2000-12-28
JP4460203B2 (en) 2010-05-12
CA2371841A1 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
US7618567B2 (en) Absorbable sponge with contrasting agent
US6440151B1 (en) Device and method for facilitating hemostasis of a biopsy tract
US8050741B2 (en) Device and method for facilitating hemostasis of a biopsy tract
US6447534B2 (en) Device and method for facilitating hemostasis of a biopsy tract
AU748773B2 (en) System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6540735B1 (en) System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
EP1383452A1 (en) Method of hydrating a sponge material for delivery to a body
AU7715600A (en) Device and method for determining a depth of an incision
AU2005202005A1 (en) Absorbable sponge with contrasting agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: SUB-Q, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ASHBY, MARK;SING, EDUARDO CHI;REEL/FRAME:015950/0682

Effective date: 19990617

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20171117